Which biopsy method to choose when men have abnormal PSA and/or DRE, a randomized study comparing current practice with innovative practice
Not Applicable
Completed
- Conditions
- Prostate cancerCancer
- Registration Number
- ISRCTN18033113
- Lead Sponsor
- Science Technology Department of Zhejiang Province
- Brief Summary
2022 Results article in https://pubmed.ncbi.nlm.nih.gov/35852595/ (added 11/08/2022)
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Male
- Target Recruitment
- 450
Inclusion Criteria
1. Male
2. Under 85 years of age
3. Verified prostate-specific antigen (PSA) > 4 ng/ml and/or abnormal DRE
4. Provision of signed informed consent
Exclusion Criteria
1. No signed informed consent
2. Patients who have been included in published cohorts
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method